Intratumoral microbiota in pancreatic neuroendocrine tumors: Enriched bacterial biomass and diversity with association to dyslipidemia
Pancreatology · 2026-11 · 26 (7) · 1005-1016
DOI: 10.1016/j.pan.2026.08.004 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pancreatology, 2026-11. Verfasst von Yu-Fan Meng und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pancreatic Surgery, Department of General Surgery, Qilu Hospital, Shandong University, Jinan, Shandong Province, China; Department of Hep…. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Neuroendocrine Tumors, Microbiota, Dyslipidemias. Die Arbeit nennt 30 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Shandong Province Natural Science Foundation.
Abstract (Originalsprache)
BACKGROUND: Intratumoral microbiota have been implicated in several cancers, including pancreatic cancer, but data on pancreatic neuroendocrine tumors (PNETs) remain limited. METHODS: We analyzed two complementary cohorts: a retrospective formalin-fixed paraffin-embedded cohort comprising 53 primary PNETs, 26 paired adjacent non-tumor tissues (ANTs), and 5 liver metastases assessed by fluorescence in situ hybridization (FISH); and a prospective subset of 25 paired fresh tumor-center and ANT samples analyzed by 16S rRNA gene sequencing. Taxonomic composition, alpha and beta diversity, differential abundance, predicted microbial functions, and associations with clinicopathological features and fasting serum lipids were evaluated. RESULTS: PNETs showed a higher frequency of detectable bacterial signals and greater microbial richness and diversity than ANTs. LEfSe identified 38 nominally differentially abundant taxa (P 2.5), including enrichment of Blautia, Rothia, and Ferrovibrio in tumors. Their combined abundance differentiated PNETs from ANTs with an area under the curve of 0.843. Exploratory functional inference suggested enrichment of 15 pathways in PNETs, including fatty acid and short-chain fatty acid biosynthesis pathways. Serum high-density lipoprotein levels were inversely associated with intratumoral microbial richness (Ace index: r = -0.497, P = 0.049). CONCLUSIONS: PNETs exhibited greater bacterial burden, microbial richness, and diversity than ANTs, with distinct taxonomic patterns and lipid-related associations. These exploratory findings warrant external validation in larger cohorts with rigorous low-biomass contamination control.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Pancreatic Surgery, Department of General Surgery, Qilu Hospital, Shandong University, Jinan, Shandong Province, China; Department of Hepatobiliary Surgery, Jining First People's Hospital, Jining, Shandong,…
- Division of Pancreatic Surgery, Department of General Surgery, Qilu Hospital, Shandong University, Jinan, Shandong Province, China.
- Division of Pancreatic Surgery, Department of General Surgery, Qilu Hospital, Shandong University, Jinan, Shandong Province, China. Electronic address: zhanhanxiang@hotmail.com.
Förderung
- National Natural Science Foundation of China
- Shandong Province Natural Science Foundation
Zitieren
APA
Meng, Y. F., Liu, L. Y., Fan, Z. Y., & Zhan, H. X. (2026). Intratumoral microbiota in pancreatic neuroendocrine tumors: Enriched bacterial biomass and diversity with association to dyslipidemia. Pancreatology, 26(7), 1005-1016. https://doi.org/10.1016/j.pan.2026.08.004
Vancouver
Meng YF, Liu LY, Fan ZY, Zhan HX. Intratumoral microbiota in pancreatic neuroendocrine tumors: Enriched bacterial biomass and diversity with association to dyslipidemia. Pancreatology. 2026;26(7):1005-1016. doi:10.1016/j.pan.2026.08.004
BibTeX
@article{Meng2026,
author = {Meng, Yu-Fan and Liu, Long-Yu and Fan, Zhi-Yao and Zhan, Han-Xiang},
title = {Intratumoral microbiota in pancreatic neuroendocrine tumors: Enriched bacterial biomass and diversity with association to dyslipidemia},
journal = {Pancreatology},
year = {2026},
volume = {26},
number = {7},
pages = {1005--1016},
doi = {10.1016/j.pan.2026.08.004}
}
EUVIMED